Bisphosphonates in breast cancer

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 753-764

  Mathew, Aju ^a   Brufsky, Adam ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

bisphosphonates; breast cancer; clodronate; pamidronate; pamidronic acid; zoledronate; zoledronic acid

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID; AROMATASE INHIBITORS; DIPHOSPHONATES;

ABDOMINAL PAIN; ARTHRALGIA; BONE ATROPHY; BONE INFECTION; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; EARLY CANCER; ESOPHAGITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOCALCEMIA; INJECTION SITE REACTION; JAW OSTEONECROSIS; JAW PAIN; KIDNEY FAILURE; LIVER DYSFUNCTION; METASTASIS INHIBITION; NAUSEA; NEPHROTOXICITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; FEMALE; HUMANS; PATHOLOGY; SECONDARY;

AROMATASE INHIBITORS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 84931563897     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28965     Document Type: Review

References (55)

1. Van Poznak CH, Temin S, Yee GC, et al., American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-7.
2. Hadji P, Body JJ, Aapro MS, et al., Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-16.
3. Wong MH, Stockler MR, Pavlakis N,. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012; 2: CD003474.
4. van der Pluijm G, Vloedgraven H, van Beek E, et al., Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698-705.
5. Wood J, Bonjean K, Ruetz S, et al., Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-61.
6. Holen I, Coleman RE,. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010; 12: 214.
7. Mathew A, Brufsky A,. Decreased risk of breast cancer associated with oral bisphosphonate therapy. Breast Cancer 2012; 4: 75-81.
8. Brufsky A,. Adjuvant bisphosphonates for early-stage breast cancer. Lancet Oncol 2011; 12: 610-1.
9. Coleman RE, Marshall H, Cameron D, et al., Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-405.
10. Gnant M, Mlineritsch B, Schippinger W, et al., Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-91.
11. Russell RG, Rogers MJ,. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
12. Tabane K, Vorobiof DA,. Bone targeted therapies in early breast cancer. Curr Treat Options Oncol 2011; 12: 412-23.
13. Dunford JE, Rogers MJ, Ebetino FH, et al., Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006; 21: 684-94.
14. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ,. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-9.
15. Green JR,. Bisphosphonates: preclinical review. Oncologist 2004; 9 (Suppl 4): 3-13.
16. Boissier S, Ferreras M, Peyruchaud O, et al., Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-54.
17. Jagdev SP, Coleman RE, Shipman CM, et al., The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126-34.
18. Theriault RL,. The role of bisphosphonates in breast cancer. J Natl Compr Cancer Netw 2003; 1: 232-41.
19. Pavlakis N, Schmidt R, Stockler M,. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005: CD003474.
20. Paterson AH, Powles TJ, Kanis JA, et al., Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
21. Kristensen B, Ejlertsen B, Groenvold M, et al., Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246: 67-74.
22. Hortobagyi GN, Theriault RL, Porter L, et al., Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785-91.
23. Theriault RL, Lipton A, Hortobagyi GN, et al., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-54.
24. Body JJ, Diel IJ, Lichinitser MR, et al., Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-405.
25. Diel IJ, Body JJ, Lichinitser MR, et al., Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004; 40: 1704-12.
26. Body JJ, Diel IJ, Lichinitzer M, et al., Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-7.
27. Kohno N, Aogi K, Minami H, et al., Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314-21.
28. Rosen LS, Gordon DH, Dugan W, Jr, et al., Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36-43.
29. Barrett-Lee P, Casbard A, Abraham J, et al., Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 2014; 15: 114-22.
30. Body JJ, Diel IJ, Bell R, et al., Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111: 306-12.
31. Amir E, Seruga B, Niraula S, et al., Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103: 1299-309.
32. Brufsky AM,. Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors. Curr Oncol Rep 2008; 10: 18-26.
33. Brufsky AM,. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008; 13: 187-95.
34. Delmas PD, Balena R, Confravreux E, et al., Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 955-62.
35. Saarto T, Blomqvist C, Valimaki M, et al., Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 1341-7.
36. Saarto T, Blomqvist C, Valimaki M, et al., Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997; 75: 602-5.
37. Greenspan SL, Brufsky A, Lembersky BC, et al., Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008; 26: 2644-52.
38. Lester JE, Dodwell D, Purohit OP, et al., Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2008; 14: 6336-42.
39. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al., Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9: 840-9.
40. Hines SL, Mincey B, Dentchev T, et al., Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009; 117: 603-9.
41. Van Poznak C, Hannon RA, Mackey JR, et al., Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28: 967-75.
42. Brufsky AM, Harker WG, Beck JT, et al., Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118: 1192-201.
43. Llombart A, Frassoldati A, Paija O, et al., Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012; 12: 40-8.
44. Coleman R, de Boer R, Eidtmann H, et al., Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405.
45. Diel IJ, Solomayer EF, Costa SD, et al., Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63.
46. Saarto T, Vehmanen L, Virkkunen P, et al., Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43: 650-6.
47. Powles T, Paterson S, Kanis JA, et al., Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24.
48. Gnant M, Mlineritsch B, Stoeger H, et al., Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-41.
49. Paterson AH, Anderson SJ, Lembersky BC, et al., Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-42.
50. von Minckwitz G, Mobus V, Schneeweiss A, et al., German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3531-9.
51. Coleman R, Gnant M, Paterson A, et al., On Behalf of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG)'s Bisphosphonate Working Group. Cancer Res 2013; 73 (24 Suppl):Abstract nr S4-07.
52. National Comprehensive Cancer Network. Breast Cancer (Version 3.2014). Available at: http://www.nccn.org/professionals/physician-gls/pdf/bone.pdf. Accessed February 6, 2014.
53. Pazianas M, Miller P, Blumentals WA, et al., A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-58.
54. Saad F, Brown JE, Van Poznak C, et al., Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-7.
55. Brufsky AM, Sereika SM, Mathew A, et al., Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J 2013; 19: 504-11.